Parkinson Disease
Conditions
Keywords
Parkinsonian Disorders, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Movement Disorders, Neurodegenerative Diseases, Dopamine Agonist, Dopamine Therapy
Brief summary
The primary purpose of the study is to evaluate the bioequivalence (BE) of tavapadon 15 milligram (mg) tablet to 3x5 mg tablets in participants with Parkinson's disease.
Interventions
DRUGTavapadon
Oral tablets
Sponsors
Cerevel Therapeutics, LLC
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
45 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Body mass index of 17.5 to 38.0 kilograms per square meter (kg/m\^2), inclusive, and total body weight \>50 kg (110 pounds \[lb\]) at Screening. 2. Participants with a diagnosis of Parkinson's disease (PD) that is consistent with the United Kingdom (UK) Parkinson's Disease Society Brain Bank diagnostic criteria. 3. Must be modified Hoehn & Yahr Stage I-III inclusive. 4. Must be on a stable dose of L-Dopa of at least 300 mg daily in conjunction with a dopa-decarboxylase inhibitor (e.g., L-Dopa/carbidopa, L Dopa/carbidopa/entacapone or L-Dopa/benserazide) administered at least 3 times per day for at least 2 weeks prior to the Day 1 Visit.
Exclusion criteria
1. Participants with a history or clinical features consistent with essential tremor, atypical or secondary parkinsonian syndrome (including, but not limited to, progressive supranuclear palsy, multiple system atrophy, cortico-basal degeneration, or drug-induced or poststroke parkinsonism). 2. Participants with a history of psychosis or hallucinations within the previous 12 months. 3. Participants with epilepsy, or history of epilepsy, or conditions that lower seizure threshold, seizures of any etiology (including substance or drug withdrawal), or who have increased risk of seizures as evidenced by history of electroencephalogram with epileptiform activity are excluded. Participants with a history of febrile seizures only are allowed with medical monitor approval. 4. History of substance or alcohol-use disorder (excluding nicotine; Diagnostic and Statistical Manual of Mental Disorders, 5th edition criteria) within 2 years prior to signing the informed consent form (ICF). 5. Participants who answer Yes on the C-SSRS Suicidal Ideation Item 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) and whose most recent episode meeting criteria for this C-SSRS Item 4 occurred within the last 6 months, OR Participants who answer Yes on the C-SSRS Suicidal Ideation Item 5 (Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting criteria for this C-SSRS Item 5 occurred within the last 6 months OR Participants who answer Yes on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years, OR Participants who, in the opinion of the investigator, present a serious risk of suicide. 6. Participants who have attempted suicide in the past. 7. Positive result for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody with detectable viral ribonucleic acid (RNA) levels at Screening. 8. Have been diagnosed with symptomatic coronavirus disease (COVID-19) or test positive (i.e., using polymerase chain reaction \[PCR\] or rapid antigen test) for COVID-19 within 30 days prior to signing the ICF. 9. Participants taking strong or moderate cytochrome P450 family 3 subfamily A member 4 (CYP3A4) inducers or inhibitors or who would be likely to require concomitant therapy with CYP3A4 inducers or inhibitors during the trial. NOTE: Other protocol-defined inclusion and
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 |
| Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCτ) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Trough Concentration (Ctrough) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | — |
| Time of Maximum Observed Concentration (Tmax) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | — |
| Degree of Fluctuation [(Cmax - Cmin)/Cavg,ss] of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | — |
| Peak-to-Trough Ratio (PTR) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | — |
| Swing [(Cmax - Cmin)/Cmin,ss] of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | — |
| Apparent Clearance of Tavapadon From Plasma (CL/F) | Pre-dose and at multiple timepoints post-dose up to Day 28 | — |
| Minimum Steady-state Plasma Concentration (Cmin,ss) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | — |
| Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Values | Up to Day 29 | — |
| Number of Participants With Clinically Significant Changes in Vital Sign Values | Up to Day 29 | — |
| Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments | Up to Day 29 | — |
| Number of Participants With Clinically Significant Changes in Physical and Neurological Examination Results | Up to Day 29 | — |
| Changes in Suicidality Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS) | Up to Day 29 | The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk. |
| Number of Participants With Adverse Events (AEs) and AEs by Severity | Up to Day 36 | — |
| Average Steady-state Plasma Concentration (Cavg,ss) of Tavapadon | Pre-dose and at multiple timepoints post-dose up to Day 28 | — |
Countries
United States
Outcome results
None listed